期刊
ENDOCRINOLOGY AND METABOLISM
卷 36, 期 3, 页码 544-552出版社
KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2021.301
关键词
Osteoporosis, postmenopausal; Diphosphonates; Denosumab; Duration of therapy
Osteoporosis is a chronic condition that cannot be cured, with a major gap in primary prevention of fractures. Case finding strategies and pharmacological interventions are available to provide lifelong fracture protection, with the benefits of osteoporosis therapies far outweighing the rare risks.
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据